SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion

Area of Science:

• Cancer biology and immunology
• Molecular mechanisms of immune evasion

Background:

• Genomic instability can initiate anti-tumor immune responses.
• Cancer cells frequently evade immune surveillance via immune checkpoints like PD-L1.
• Understanding regulators of immune evasion is crucial for effective cancer immunotherapy.

Purpose of the Study:

• To identify novel factors contributing to cancer immune evasion.
• To elucidate the dual role of SMARCAL1 in suppressing innate immunity and promoting PD-L1 expression.
• To evaluate SMARCAL1 as a therapeutic target for enhancing anti-tumor immunity.

Main Methods:

• Investigated the function of SNF2-family DNA translocase SMARCAL1 in cancer cells.
• Assessed the impact of SMARCAL1 on cGAS-STING innate immune signaling pathways.
• Analyzed SMARCAL1's role in regulating PD-L1 expression via chromatin accessibility and JUN cooperation.
• Utilized a mouse melanoma model to study the effects of SMARCAL1 loss on tumor immunity and response to checkpoint blockade.

Main Results:

• SMARCAL1 suppresses innate immune signaling by limiting endogenous DNA damage, thereby inhibiting cGAS-STING activation.
• SMARCAL1 cooperates with JUN to maintain chromatin accessibility at the PD-L1 locus, promoting PD-L1 expression.
• Loss of SMARCAL1 impairs PD-L1 induction under genomic stress, enhances anti-tumor immune responses, and improves sensitivity to immune checkpoint blockade in vivo.

Conclusions:

• SMARCAL1 acts as a key mediator of tumor immune evasion through a dual mechanism.
• Targeting SMARCAL1 could overcome immune resistance in cancer.
• SMARCAL1 inhibition represents a promising strategy to potentiate cancer immunotherapy.